1 / 29

Cardiology Journal Club

Cardiology Journal Club. Sanjay Dravid, M.D. January 17, 2006. MULTIPLE BIOMARKERS FOR THE PREDICTION OF FIRST MAJOR CARDIOVASCULAR EVENTS AND DEATH . Wang, Thomas J., et al. Massachusetts General Hospital. NEJM. Volume 355(25), 21 December 2006, pp 2631-2639. Overview.

luther
Download Presentation

Cardiology Journal Club

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Cardiology Journal Club Sanjay Dravid, M.D. January 17, 2006

  2. MULTIPLE BIOMARKERS FOR THE PREDICTION OF FIRST MAJOR CARDIOVASCULAR EVENTS AND DEATH • Wang, Thomas J., et al. • Massachusetts General Hospital. • NEJM. Volume 355(25), 21 December 2006, pp 2631-2639.

  3. Overview • To evaluate the incremental usefulness of multiple biomarkers from various pathways. • Established risk factors, including smoking, htn, DM, and dyslipidemia. • Significant interest in new biomarkers for risk stratification of ambulatory persons.

  4. Novel Approach • Many individual biomarkers have been studied. • “Multimarker” Approach • Simultaneous measurement may enhance risk stratification?

  5. Outcomes Analysis • 1. Death from any cause • 2. 1st Major cardiovascular event (MI, coronary insufficiency, heart failure, and stroke. • Reviewed by a committee of three investigators

  6. Study Sample • Large, community based cohort study • Participants from the sixth examination cycle (1995-1998) of the Framingham Offspring Study • IRB of Boston University Medical Center approval • Written informed consent was obtained • H & P, PE, and Lab Assessment

  7. Exclusion Criteria • Serum creatinine levels greater than 2.0 mg/dL • Missing covariates • Prior event when determining outcome of major cardiovascular event • Triglycerides > 400

  8. Biomarker Selection • 1. Marker of inflammation- hsCRP • 2. Markers of neurohormonal activity- BNP, aldosterone, renin, N-terminal pro-atrial natriuretic peptide • 3. Marker of thrombosis and inflammation- fibrinogen • 4. Marker of fibrinolytic potential and endothelial function- plasminogen-activator

  9. Biomarker cont’d • Inhibitor type 1 • 5. Marker of thrombosis- D-dimer • 6. Marker of endotheial function and oxidant stress- homocysteine • 7. Marker of glomerular endothelial function- urinary albumin-to-creatinine ratio

  10. Lab Protocol • Fasting blood and urine samples collected in morning after patient supine for ~10 minutes. Immediately centrifuged and stored at -70 degreesC. • Standardized Assay Methods

  11. Statistical Analysis • Multivariable proportional-hazards model (2 sets of analyses for each outcome due to urine subgroups) • Logarithmic transformation used to normalize the distribution of biomarkers • To reduce the number of false positives from multiple testing:

  12. Statistics cont’d • 1) Multivariable Cox regression model • 2) Backward elimination • 3) Construction of multimarker score • 4) Quintiles categorized • 5) Cumulative probability curves constructed by the Kaplan-Meier method for low, intermediate and high mulitmarker scores

  13. Statistics cont’d • Then calculated hazard ratios for death and major cardiovascular events for the mulitmarker score groups • Adjusted for age, sex, conventional risk factors including htn, smoking, dm, etc. • “C statistic” • ROC curves

  14. Statistics cont’d • Secondary Analysis adjusting for medication use • Repeated a Cox proportional-hazards model for major cardiovascular events adjusting for “nonmajor events”  angina, intermittent claudication, TIA • SAS software, version 8 (SAS Institute)

  15. C Statistic • Defined as the probability of concordanc among persons who can be compared. • Estimated as the sum of concordance values divided by the number of comparable pairs. • Better able to measure discrimination than relative risk.

  16. Results • Total of 3532 persons- 21 excluded for serum creatinine and 302 for missing covariates. • 10 year follow-up (median 7.4 years) 3209 available for study. • 207 (6%) died, of whom 72 were women • 169 (6%, excluding prevalent CV disease at baseline) had a major cardiovascular event, of whom 68 were women

  17. Results cont’d • Biomarker panel for nine: P<0.001 for death and P=0.005 for cardiovascular events • Biomarker panel for ten (2750 persons): P<0.001 for death and P=0.04 for cardiovascular events

  18. Results cont’d • Backward elimination models: final statistical model included only the following biomarkers: BNP, homocysteine, urinary albumin-to-creatinine ratio and renin for death. BNP and urinary albumin-to-creatinine ratio for major cardiovascular events.

  19. Utility of Multimarker Scores • Backward elimination biomarkers selected as statistically significant were incorporated into mulitmarker scores. • Restricted to urine sample patients: 1) death from any cause, the number of events and number at risk were 172 and 2750, respectively; 2) major cardiovascular events, 133 and 2598, respectively.

  20. Utility? • Persons with high multimarker scores had a risk of death four times as great and a risk of major cariovascular events almost two times as great as persons with low mulitmarker scores. • (P<0.001 and P=0.02, respectively)

  21. Discussion • ~10 year study of biomarkers indicating BNP, hsCRP, homocysteine, renin, and alb/Cr ratio as most informative for predicting death, while BNP and alb/Cr ration as significant for predicting cardiovascular outcome. • Although high multimarker scores conferred greater risk for death and major cardiovascular events…

  22. Conclusion • Mulitmarker scores (combination of biomarkers) add only moderately to conventional risk factors as evidenced by small changes in C statistic. • Single biomarkers may have correlation with predicting outcomes • Panel likely will not be useful or cost-effective in ambulatory setting for further risk stratification

  23. Limitations • Biomarker selection: omission of lipoprotein-associated phospholipase A2 • Each individual marker not independently tested • Not a true cohort study to asses for primary prevention as “nonmajor” cardiovascular events adjusted • Adiposity or insulin resistance not taken into account

  24. Summary • Biomarkers from multiple, biologically distinct pathways are associated with the risks of death and major cardiovascular events. • However, only moderately adds to conventional risk factors currently.

More Related